NEW YORK (GenomeWeb) – Agendia today announced a new deal with Daiichi Sankyo to use Agendia's oncology biomarker technology to evaluate new drugs from the Japanese drug firm currently in clinical trials.
As part of the deal, Agendia's technology will be used to assess patient samples. Financial and other terms were not disclosed.
"This exciting early stage research collaboration represents a potential new area for additional commercialization and expansion of Agendia's platform technology," Agendia President and CEO David Macdonald said in a statement. "With this new agreement, our molecular diagnostics technology will now be applied to additional areas of oncology research."